Divergent clonal evolution of castration resistant neuroendocrine prostate cancer
暂无分享,去创建一个
Matteo Benelli | Clarisse Marotz | Davide Prandi | Levi A Garraway | Francesca Demichelis | Eugenia G. Giannopoulou | Olivier Elemento | Andrea Sboner | Juan Miguel Mosquera | Mark A Rubin | David M Nanus | Eliezer M Van Allen | Himisha Beltran | S. Varambally | M. Rubin | O. Elemento | L. Garraway | A. Sboner | E. V. Van Allen | H. Beltran | J. Mosquera | S. Tomlins | F. Demichelis | M. Benelli | L. Puca | B. V. Chakravarthi | D. Prandi | S. Tagawa | D. Nanus | C. Marotz | Scott A Tomlins | Sooryanarayana Varambally | J. Cyrta | Loredana Puca | Joanna Cyrta | Scott T Tagawa | Balabhadrapatruni V S K Chakravarthi | Eugenia Giannopoulou
[1] Ximing J. Yang,et al. Small Cell Carcinoma of the Prostate: An Immunohistochemical Study , 2006, The American journal of surgical pathology.
[2] M. Rubin,et al. Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.
[3] C. Bieberich,et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate , 2009, The Prostate.
[4] Jun Yu,et al. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. , 2011, Cancer research.
[5] Levi Garraway,et al. SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines , 2008, Nucleic acids research.
[6] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[7] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[8] Alessandro Romanel,et al. Unraveling the clonal hierarchy of somatic genomic aberrations , 2014, Genome Biology.
[9] Francine E. Garrett-Bakelman,et al. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles , 2012, Genome Biology.
[10] Mark Gerstein,et al. RSEQtools: a modular framework to analyze RNA-Seq data using compact, anonymized data summaries , 2010, Bioinform..
[11] Vladimir Vacic,et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.
[12] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[13] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[14] S. Varambally,et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.
[15] A. Ashworth,et al. The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate Notch signalling , 2014, Oncotarget.
[16] P. Bourne,et al. CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt , 2012, Nature Communications.
[17] Eugenia G. Giannopoulou,et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer , 2014, Nature Communications.
[18] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[19] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[20] F. Demichelis,et al. Tumor clone dynamics in lethal prostate cancer , 2014, Science Translational Medicine.
[21] Bernhard O. Palsson,et al. Cancer cell lines , 1999 .
[22] M. Nykter,et al. The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.
[23] C. Huggins,et al. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.
[24] M. Rubin,et al. Next-generation Prostate Cancer Biobanking: Toward a Processing Protocol Amenable for the International Cancer Genome Consortium , 2012, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[25] W. Lam,et al. Polycomb-mediated silencing in neuroendocrine prostate cancer , 2015, Clinical Epigenetics.
[26] Jiao Zhang,et al. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] David C. Smith,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[28] Kristian Cibulskis,et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data , 2011, Bioinform..
[29] C. Logothetis,et al. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. , 2013, Cancer discovery.
[30] Marc Ladanyi,et al. Bringing the genomic landscape of small-cell lung cancer into focus , 2012, Nature Genetics.
[31] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[32] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[33] A. Berruti,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[34] R. Vessella,et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.
[35] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[36] S. Varambally,et al. Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.
[37] Joshua M. Stuart,et al. A basal stem cell signature identifies aggressive prostate cancer phenotypes , 2015, Proceedings of the National Academy of Sciences.
[38] Wennuan Liu,et al. Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.
[39] M. Rubin,et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. , 2013, Neoplasia.
[40] M. Rubin,et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] D. Ghosh,et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. , 2007, Cancer research.
[42] E. Wieben,et al. The genomic landscape of small intestine neuroendocrine tumors. , 2013, The Journal of clinical investigation.
[43] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[44] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[45] David C. Corney,et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.
[46] M. Rubin,et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. , 2012, Cancer discovery.
[47] Alessandro Romanel,et al. ASEQ: fast allele-specific studies from next-generation sequencing data , 2015, BMC Medical Genomics.
[48] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[49] M. Rubin,et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. , 2014, Cancer research.
[50] Michael R Hamblin,et al. CA : A Cancer Journal for Clinicians , 2011 .
[51] David Z. Chen,et al. METHOD Open Access , 2014 .
[52] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[53] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[54] M. Fraga,et al. The Polycomb group protein EZH2 directly controls DNA methylation , 2006, Nature.
[55] C. Liang,et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. , 2012, Endocrine-related cancer.
[56] S. Carr,et al. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer , 2014, Science.
[57] Ming Yu,et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer , 2014, Nature Communications.
[58] Jing Chen,et al. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization , 2009, Nucleic Acids Res..
[59] T. Golub,et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.
[60] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[61] H. Scher,et al. Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer , 2009, Clinical Cancer Research.
[62] M. Rubin,et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. , 2013, European urology.
[63] Joshua J. Steffan,et al. The Transcription Factor SPDEF Suppresses Prostate Tumor Metastasis* , 2012, The Journal of Biological Chemistry.
[64] Brent S. Pedersen,et al. Pybedtools: a flexible Python library for manipulating genomic datasets and annotations , 2011, Bioinform..
[65] A. Aparicio,et al. Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. , 2014, Oncology.
[66] M. Gerstein,et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.
[67] Trevor J Pugh,et al. Oncotator: Cancer Variant Annotation Tool , 2015, Human mutation.
[68] B. Sander,et al. A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma , 2013, Epigenetics.
[69] V. Arora,et al. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.
[70] W. Isaacs,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.
[71] Kyung Park,et al. Epigenomic alterations in localized and advanced prostate cancer. , 2013, Neoplasia.
[72] Yibing Ma,et al. Mechanisms Underlying Cancer Growth and Apoptosis by DEK Overexpression in Colorectal Cancer , 2014, PloS one.
[73] Carissa A. Sanchez,et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.
[74] A. Sivachenko,et al. Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.
[75] Dennis C. Friedrich,et al. Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .
[76] S. Tagawa. Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] Lily Wu,et al. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines , 2010, The Prostate.
[78] Robert H. Bell,et al. The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. , 2015, Cell reports.